section name header

Pronunciation ⬇

klin-da-MYE-sin

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Indications ⬆ ⬇

IM:

REMS

Unlabeled Use:

Action ⬆ ⬇

  • Inhibits protein synthesis in susceptible bacteria at the level of the 50S ribosome.
Therapeutic effects:
  • Bactericidal or bacteriostatic, depending on susceptibility and concentration.

Spectrum:

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following PO/IM administration. Minimal absorption following topical/vaginal use.

Distribution: Widely distributed. Does not significantly cross blood-brain barrier. Crosses the placenta; enters breast milk.

Protein Binding: 94%.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme.

Half-Life: Neonates: 3.6–8.7 hr; Infants up to 1 yr: 3 hr; Children and adults: 2–3 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid60 min6–8 hr
IMrapid1–3 hr6–8 hr
IVrapidend of infusion6–8 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: arrhythmias, hypotension

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria

GI: diarrhea, CDAD, bitter or metallic taste, esophagitis, esophageal ulcer, nausea, vomiting

Local: local irritation (topical products), phlebitis at IV site

Neuro: dizziness, headache, vertigo

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Cleocin, Cleocin T, Clinda-Derm, Clindagel, Clindesse, Clindets, Xaciato

Canadian Brand Names ⬆ ⬇

Clinda-T, Dalacin C, Dalacin Vaginal

Code ⬆

NDC Code